AIMS: Concerns have been raised about patients' failure to persist in alcohol treatment. We examined prescriptions for oral naltrexone in a large, nationally distributed treatment population to identify characteristics and health-care utilization patterns associated with persistence. DESIGN: Data from the 2000-2004 MarketScan Commercial Claims and Encounters Database were used to identify patients with alcohol-related claims who were prescribed naltrexone. MEASUREMENTS: Analysis identified patient characteristics that predicted persistence with naltrexone (defined as having filled prescriptions for >or=80% of the 6-month treatment period) and its association to health-care utilization. FINDINGS: Of 1138 patients, 162 (14.2%) were persistent in obtaining naltrexone. Non-persistent patients were significantly younger, more likely to be hourly employees and to live in an area with a lower median income, and less likely to be newly diagnosed with an alcohol-related disorder. Non-persistence in obtaining naltrexone was associated with significantly more intensive treatments, including inpatient detoxification, emergency room visits and hospitalizations. CONCLUSIONS: Over a 6-month period, 85.8% of patients who filled an initial prescription for naltrexone did not persist in obtaining the medication. Non-persistence was associated with significantly greater use of costly health-care services. Because the study was correlational, it is not possible to conclude that persistence reduced health-care costs, as patients with a better prognosis may have been more persistent. Research is needed to determine whether interventions that enhance persistence with naltrexone therapy improve treatment outcomes and reduce health-care costs.
AIMS: Concerns have been raised about patients' failure to persist in alcohol treatment. We examined prescriptions for oral naltrexone in a large, nationally distributed treatment population to identify characteristics and health-care utilization patterns associated with persistence. DESIGN: Data from the 2000-2004 MarketScan Commercial Claims and Encounters Database were used to identify patients with alcohol-related claims who were prescribed naltrexone. MEASUREMENTS: Analysis identified patient characteristics that predicted persistence with naltrexone (defined as having filled prescriptions for >or=80% of the 6-month treatment period) and its association to health-care utilization. FINDINGS: Of 1138 patients, 162 (14.2%) were persistent in obtaining naltrexone. Non-persistent patients were significantly younger, more likely to be hourly employees and to live in an area with a lower median income, and less likely to be newly diagnosed with an alcohol-related disorder. Non-persistence in obtaining naltrexone was associated with significantly more intensive treatments, including inpatient detoxification, emergency room visits and hospitalizations. CONCLUSIONS: Over a 6-month period, 85.8% of patients who filled an initial prescription for naltrexone did not persist in obtaining the medication. Non-persistence was associated with significantly greater use of costly health-care services. Because the study was correlational, it is not possible to conclude that persistence reduced health-care costs, as patients with a better prognosis may have been more persistent. Research is needed to determine whether interventions that enhance persistence with naltrexone therapy improve treatment outcomes and reduce health-care costs.
Authors: Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman Journal: Mayo Clin Proc Date: 2006-08 Impact factor: 7.616
Authors: Helen M Pettinati; Roger D Weiss; William Dundon; William R Miller; Dennis Donovan; Denise B Ernst; Bruce J Rounsaville Journal: J Stud Alcohol Suppl Date: 2005-07
Authors: Joanne LaFleur; Clinton J Thompson; Vijay N Joish; Scott L Charland; Gary M Oderda; Diana I Brixner Journal: Ann Pharmacother Date: 2006-07-18 Impact factor: 3.154
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Archana Krishnan; Frederick L Altice Journal: Drug Alcohol Depend Date: 2017-03-10 Impact factor: 4.492
Authors: Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley Journal: Alcohol Clin Exp Res Date: 2008-11-25 Impact factor: 3.455